The Australian Advantage

Leading Expertise And Technology For Development Of Novel Therapeutics, Vaccines And Diagnostics

Home Solutions Phases Clinical Australian Advantage

The advanced laboratory facilities in Melbourne serve as our Australian headquarters, where we specialize in and are passionate about using cutting-edge thinking and technology to support the development of novel therapeutics, vaccines and diagnostics. 

We are Australia’s most comprehensive specialty laboratory for therapeutic, vaccine and diagnostics development. We develop and conduct pharmacokinetic (PK) and pharmacodynamic (PD) assays across a wide variety of therapeutic areas providing a one stop shop for all of your clinical trial requirements. 

The Australian Advantage 

Australia is the jurisdiction of choice for conducting early phase clinical trials with three major
advantages, Speed, Cost and Quality.

028 – Limited Time Created with Sketch.

Speed:

With the country’s fast and pragmatic regulatory environment for Phase 1 clinical studies, there is an average 4-6 weeks for review and approval for healthy volunteer studies due to IND not being required to conduct clinical trials in Australia. 

083 – Money Bag Created with Sketch.

Cost:

The Australian government offers an attractive R&D tax incentives including cash rebates to eligible companies. According to a cost comparison study, Australia is ~30% cheaper than the US before tax incentives; and 60% cheaper after tax incentives for conducting your clinical trials.

003 – Magnifying Glass Created with Sketch.

Quality:

Australia is an OECD member resulting in mutual acceptance of data by global regulatory bodies. Data from studies conducted in Australia can be used to support international regulatory applications, including the US FDA and European Medicines Evaluation Agency (EMEA).

The advantages of Australia as an early phase location for clinical trials provides multiple options for our customers. Whether it’s starting your Phase 1 trial in Australia and transitioning to our global BioAgilytix team for Phase 2+ or choosing to conduct your clinical studies in the USA or Europe, BioAgilytix can provide a solution for all of your clinical requirements. 

peers walking in the hallway

Our Australian headquarters

BioAgilytix operates via its Australian affiliate, 360biolabs, a BioAgilytix company.

The advanced laboratory facilities in Melbourne serve as our Australian headquarters, where we specialise in and are passionate about using cutting-edge thinking and technology to support the development of novel therapeutics, vaccines and diagnostics.

We are Australia’s most comprehensive specialty laboratory for therapeutic, vaccine and diagnostics development. We develop and conduct pharmacokinetic (PK) and pharmacodynamic (PD) assays across a wide variety of therapeutic areas providing a one stop shop for all of your clinical trial requirements.

Two Australian locations to support all of your needs

BioAgilytix has two locations in Australia in order to best serve the needs of our partners and
customers.

melbourne australia

Melbourne Lab 

Our Melbourne location is at the leading Burnet Institute, situated in one of Australia’s key biomedical and clinical research hubs and is co-located with Australia’s largest Phase 1 unit, which makes us well-positioned to support your clinical requirements. Our Melbourne laboratory operates both BSL 2 and 3 laboratories.

85 Commercial Road, Melbourne
brisbane's bridge

Brisbane Lab  

Our Brisbane location is at the Translational Research Institute (TRI) within the Princess Alexandra Hospital. With its focus on effective translation of innovative medical research, the close physical and intellectual collaboration between academia, industry and clinicians facilitates BioAgilytix’s mission of enabling the breakthroughs of tomorrow today.

37 Kent St, Woolloongabba

Proven track record of advancing therapeutic drugs, biomolecules and vaccines through clinical development

Our industry experienced chemistry and biology teams enjoy the challenges of developing, validating and conducting sensitive quantitative determinations, metabolite identification and other complex analytical requests. Our immunology experts offer comprehensive analytical support for complex biologics, extensive immune monitoring capabilities, and the flexibility and knowledge to develop assays for new technologies. Our classically trained virology team, have a wealth of industry experience, have worked with most virus families known to science and add to the breadth and depth of BioAgilytix’s capabilities. We have the capacity to support bioanalysis for new and established small molecules, peptides, proteins and large molecules by offering services such as:

  • Pharmacokinetic assessment 
  • Pharmacodynamic assessment 
  • Virology 
  • Central Laboratory Services
  • Immunogenicity Assessment 
lab team looking at specimen

Passionate team looking to provide quality service to advance therapeutics

BioAgilytix has a team of exceptional biologists and chemists with global pharma and biotech industry experience and a proven track record of advancing therapeutic drugs, biomolecules and vaccines through clinical development.

We have the technical knowledge and experience to deliver accurate, reproducible and robust assay data which will progress your therapeutic through regulatory review. We are dedicated to providing a quality service that efficiently delivers results, and are proud of our reputation as a highly-skilled team with an agile and responsive approach to study management and communication.

  • Science-driven to create future medicines.
  • Quality control systems that provide excellence.
  • High-performing teams that achieve outstanding results.
  • Committed to accelerating your product to the next decision point.

Global BioAgilytix operates as One Team with One Mission, Enabling the breakthroughs of tomorrow today.

Learn More about BioAgilytix’s Australian Advantage

speak to a scientist